



REGENXBIO to Participate in Upcoming Investor Conferences

September 05, 2023 07:05 AM EDT

ROCKVILLE, Md., Sept. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Morgan Stanley 21st Annual Global Healthcare Conference

Fireside Chat Date: Tuesday, September 12, 2023

Fireside Chat Time: 10:10 a.m. ET

Location: New York, NY

2023 Baird Global Healthcare Conference

Fireside Chat Date: Wednesday, September 13, 2023

Fireside Chat Time: 9:40 a.m. ET

Location: New York, NY

A live webcast of the fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:

Investors:

Chris Brinzey

ICR Westwicke

339-970-2843

chris.brinzey@westwicke.com



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301916241.html>

SOURCE REGENXBIO Inc.